Aurora (ACB) Q4 2026 Earnings Transcript
Aurora Cannabis (ACB) reported fiscal 2026 net revenue of CAD 321 million, up 11% year over year, with 55% from outside Canada, and adjusted EBITDA of CAD 54 million, up 32%. The company said it had CAD 165 million cash and no debt. Management attributed growth to international medical cannabis, while fiscal 2027 guidance calls for lower revenue and adjusted EBITDA due to a 30% cut in Canadian medical reimbursement rates effective April 1.
Guidance reset tied to Canadian reimbursement cuts is the dominant near-term earnings risk, partially offset by international growth and margin outlook.
Aurora guided fiscal 2027 revenue/adjusted EBITDA lower after Canadian medical reimbursement rates dropped 30% effective April 1.
Bias toward downside/volatility until investors underwrite the magnitude of Canadian reimbursement pressure versus Germany/Poland growth and the Safari Flower accretion.
Background
Aurora’s fiscal 2026 results emphasize a pivot toward medical cannabis and away from low-margin Canadian consumer and propagation activities.
Why it matters
The transcript frames fiscal 2027 as a “reset year” driven by a 30% reduction in Canadian medical reimbursement rates, with international growth (Germany/Poland) and EU capacity expansion partially offsetting the hit.
Market relevance
Traders can reprice ACB around the explicit Canadian reimbursement headwind and the company’s stated margin and international growth offsets for fiscal 2027.
Market effects
Reinforces that Canadian medical reimbursement pricing is a key swing factor for cannabis operators’ earnings power, increasing focus on EU GMP capacity and international mix.
Highlights Germany/Poland as the primary growth engine while Canada faces a pricing reset.
EU GMP expansion and export capacity (via Safari Flower and Leuna output) may shift competitive dynamics for regulated medical supply in Europe.
Alternative perspectives
International growth and mid-to-high 50% adjusted gross margin guidance could cushion the Canadian reimbursement shock more than the market expects.
Free cash flow fell and SG&A rose (including expected credit loss), so investors should separate operating margin resilience from cash conversion and credit/FX effects.
Key entities
- companyAurora Cannabis Inc.
Reports fiscal 2026 results and provides fiscal 2027 guidance impacted by Canadian reimbursement rate cuts; discusses Safari Flower acquisition and Leuna expansion.
- executiveMiguel Martin
CEO; frames performance around medical cannabis strategy and international growth pillars.
- executiveSimona King
CFO; highlights reimbursement-driven reset and cash/earnings drivers.
